Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
29.74
-0.45 (-1.49%)
At close: Oct 7, 2025, 4:00 PM EDT
29.75
+0.01 (0.03%)
After-hours: Oct 7, 2025, 7:57 PM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 14 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $86.64, which forecasts a 191.32% increase in the stock price over the next year. The lowest target is $34 and the highest is $140.
Price Target: $86.64 (+191.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 5 | 5 | 5 |
| Buy | 10 | 9 | 9 | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 15 | 16 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +169.00% | Sep 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $105 | Buy | Reiterates | $105 | +253.06% | Sep 5, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $136 → $128 | Strong Buy | Maintains | $136 → $128 | +330.40% | Aug 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $112 → $105 | Buy | Maintains | $112 → $105 | +253.06% | Aug 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +169.00% | Jul 28, 2025 |
Financial Forecast
Revenue This Year
670.68M
from 560.23M
Increased by 19.72%
Revenue Next Year
826.88M
from 670.68M
Increased by 23.29%
EPS This Year
-5.14
from -6.29
EPS Next Year
-4.12
from -5.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 702.0M | 1.1B | |||
| Avg | 670.7M | 826.9M | |||
| Low | 628.9M | 659.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.3% | 61.0% | |||
| Avg | 19.7% | 23.3% | |||
| Low | 12.3% | -1.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.41 | -1.11 | |||
| Avg | -5.14 | -4.12 | |||
| Low | -6.56 | -5.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.